John B. Moriarty - 27 Feb 2026 Form 4 Insider Report for Avidity Biosciences, Inc. (RNA)

Role: Chief Legal Officer
Signature: /s/ Michael F. MacLean Attorney-in-Fact
Issuer symbol: RNA
Transactions as of: 27 Feb 2026
Net transactions value: $0
Form type: 4
Filing time: 27 Feb 2026, 15:17:50 UTC
Previous filing: 09 Jan 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Moriarty John B	Chief Legal Officer	C/O AVIDITY BIOSCIENCES, INC., 3020 CALLAN RD., SAN DIEGO	/s/ Michael F. MacLean Attorney-in-Fact	27 Feb 2026	0001564621

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RNA	Common Stock	Disposed to Issuer		-92,054	-100%		0	27 Feb 2026	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	RNA	Stock Option (Right to Buy)	Disposed to Issuer		-50,000	-100%		0	27 Feb 2026	Common Stock	50,000	$31.42	Direct	F2
transaction	RNA	Stock Option (Right to Buy)	Disposed to Issuer		-160,000	-100%		0	27 Feb 2026	Common Stock	160,000	$44.57	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

John B. Moriarty is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id	Content
F1	The reported securities represent shares of Common Stock (inclusive of shares of Common Stock issuable upon settlement of previously reported restricted stock units) disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of October 25, 2025 (the "Merger Agreement"), among Novartis AG ("Novartis"), Ajax Acquisition Sub, Inc., an indirect wholly owned subsidiary of Novartis, and the Issuer.
F2	The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price.

Content

The reported securities represent shares of Common Stock (inclusive of shares of Common Stock issuable upon settlement of previously reported restricted stock units) disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of October 25, 2025 (the "Merger Agreement"), among Novartis AG ("Novartis"), Ajax Acquisition Sub, Inc., an indirect wholly owned subsidiary of Novartis, and the Issuer.

The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price.